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The exploration and full development of nanostructured drug 
delivery systems (DDS) is expected to increase the chemical 
stability of the payload therapeutics upon systemic 
administration and to expand circulation time. By enlarging the 
size of the whole drug conjugate  over ~5- 8 nm, but still within 
the submicron scale (up to ~500 nm), renal clearance and 
accumulation in lung are avoided while cell penetrability is 
preserved and often enhanced [1]. The need of nanoconjugates 
for drug delivery is especially well illustrated in the case of 
cancer therapies, in which the prescribed drugs are intrinsically 
cytotoxic. 
In non-targeted antitumoral drug delivery loaded nanoparticles 
tend to escape the blood stream because of the leaky 
angiogenic endothelium and the aberrant lymphatic drainage in 
tumoral tissues. This enhanced permeability and retention effect
(EPR) [2] is exploited as a way to promote the so-called ‘passive’
drug targeting in solid tumors. However, cancer chemotherapy 
has a low therapeutic index and promotes toxic effects that 
severely compromise patients’ life quality [3].  In this context, 
innovative cancer chemotherapies pursue cell-targeted drug 
delivery to enhance the effective drug concentration in tumor 
and metastatic foci while reducing drug doses, undesired side 
effects and fabrication costs. Targeted therapy could be 
achieved by functionalization of DDS, taking advantage of the 
overexpression of specific cell surface receptors in many cancer 
cells associated to the oncogenic process. In this context, the 
large surface/volume ratio of particulate nanomaterials offers 
opportunities for multiple chemical functionalization (Figure 1 A),
aimed to recruit appropriate and sufficient agents to overcome 
the relevant barriers encountered before reaching the target 
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tissue [4], among which the most important is the cell 
membrane itself.
Cell penetrating peptides, especially those activated by features 
of cancer cells’ environment, antibodies against cell-surface 
markers or tumor homing peptides (non-antibody ligands of the 
cell surface markers) are usually sufficient to reach good 
targeting and desired biodistribution of nanoconjugates. 
Endosomal escape and nuclear migration are additional 
functions that might be incorporated to DDS to enhance the 
therapeutic potential. Reporter agents such as quantum dots, 
fluorescent dyes or radioactive components confer additional 
values regarding theragnostic applications. The recruitment of 
these and additional functions in the drug complex is achieved 
upon chemical activation of the nanoparticle surface and its 
sequential functionalization [5] (Figure 1, i, ii, iii). The 
antitumoral drug is finally incorporated to the whole 
nanoconjugate (Figure 1, iv).  
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Figure 1. Conceptual design and fabrication pipeline of 
DDS. Step-based production of conventional cell targeted DDSs 
(A) versus one-step production of protein-based nanoparticles 
for protein drug delivery upon complex upstream genetic design 
(B). i. Nanoparticles (blue spheres) can be fabricated with 
different suitable materials including metals, dendrimers, natural
and artificial polymers, carbon nanotubes, silica and others. ii. 
Before functionalization, chemical activation is performed by the
inclusion of reactive groups (green stars) to further anchor the 
bioactive molecules. Pegylation (brown layer) often minimizes 
unspecific protein adsorption of the material in complex media 
and reduces the formation of protein corona [5], which is able to 
abort the activity of surface-attached cell targeting agents [6]. 
iii. Cell surface targeting is usually achieved by the addition of 
protein ligands (red symbols), namely antibodies, antibody 
fragments, non-antibody protein ligands or other specific bio-
reactive molecules such as carbohydrates and aptamers. Other 
functional agents can be added here such as reporter molecules,
including fluorescent chemicals, radiolabels and MRI labels 
(yellow spheres) that might be useful in preclinical studies for 
theragnosis. Importantly, the chemistry of conjugation should 
desirably control the positioning of the targeting ligands to 
maximize their reactivity with cell surface receptors [5]. Nuclear 
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localization signals (NLS, dark green entities) would ensure the 
active drug being delivered into the nucleus when it is required 
for therapeutic impact. iv. The drug itself (blue ring) is generally 
incorporated in a last step, although in some cases (eg 
liposomal constructs), it would be present already during 
nanoparticle formation for encapsulation. v. Since all the 
functions described in previous steps (cell surface recognition, 
penetration, endosomal escape, nuclear migration, fluorescence 
emission and cytotoxicity) can be reached by proteins, protein-
based nanoparticles can be designed by conventional genetic 
engineering by recruiting functional domains from different 
origins (colored segments) at the upstream level. Self-
assembling domains can be also added to a single chain 
polypeptide that upon biological production, results in fully 
functional nanoparticles in which the building blocks contain the 
drug themselves. 
An alternative to the complex pipeline of heterogeneous DDS 
fabrication (Figure 1 A) is based on the protein nature of most of 
the functional agents used for cell targeting and intracellular 
trafficking, and also of many reporter fluorescent agents [7]. In 
addition, the drug itself might be a protein, since a wide set of 
cytotoxic peptides and proteins have been identified as active in
antitumoral therapies, including pro-apoptotic factors, 
disintegrins and protease or protein kinase inhibitors [3]. Many 
of them are toxins from pathogenic microorganisms or 
components of animal or plant venoms [8-10]. Protein fusion 
technologies allow combining targeting agents with cytotoxic 
moieties in single chain polypeptides, in a pharmacological trend
that is rapidly increasing [11].  A paradigm of such a drug (FDA-
approved) is denileukin diftitox (ONTAK®), in which interleukin-2
(IL-2) is fused to a Corynebacterium diphtheria toxin and 
targeted to IL-2 receptors displayed on the surface of leukemia 
and lymphoma cell types. This modular concept allows a single-
step production of the conjugate in recombinant microorganisms
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(Figure 1 B), taking advantage of the versatility, scalability and 
cost-effectiveness of biofabrication [12]. Although the 
recombinant production of proteins excludes those composed by
unnatural amino acids, the modular approach is offering 
intriguing roads in cancer nanomedicine by the generation of 
DDS based on single chain modular polypeptides. 
Over the mere production of plain polypepides, the incorporation
of self-assembling protein domains allow the generation of nano 
or micro-structured materials in which pre-defined structure and 
biological activities merge [13;14]. In this context, the 
fluorescent proteins IRFP and GFP have been recently 
engineered for a controlled self-assembly by either the addition 
of conveniently located cationic domains [15] or by the 
repositioning of inner barrel strands [16]. This approach 
generates protein-only recombinant nanoparticles with 
regulatable morphometric properties that if also containing cell-
targeting peptides, achieve all the expectations of DDS 
regarding biodistribution and targeting [17]. The generation of 
multifunctional protein-only nanoparticles not only mimic the 
recognition patterns and in vivo behaviour of natural infectious 
viruses [18] but it also provides opportunities for an ‘a la carte’ 
functional recruitment of selected peptides and protein domains 
in tailored, chemically homogenous DDS. 
The appropriate functional combination and refinement of self-
assembling, cell-targeting and cytotoxicity in protein-only 
nanoparticles should result in a new category of antitumoral 
drugs suitable to be easily designed and produced by simple, 
one step recombinant technologies (Figure 1, v). Protein-only 
DDS are then an appealing alternative to conventional drug 
nanoconjugates not only regarding they intrinsically higher 
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biocompatibility but also in the context of avoiding sequential, 
biologically unfriendly and chemically complex functionalization 
processes. 
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